Baird analyst Catherine Ramsey Schulte lowered the firm’s price target on Bio-Techne (TECH) to $61 from $62 and keeps a Neutral rating on the shares. The firm updated its model following Q1 results.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TECH:
- Bio-Techne Reports Q1 FY2026 Earnings with Strategic Focus
- Bio-Techne’s Earnings Call: Mixed Sentiment Amid Growth and Challenges
- Positive Long-Term Outlook for Bio-Techne Amid Short-Term Challenges
- Bio-Techne: Strong Profitability and Growth Potential Amidst Challenges Justify Buy Rating
- Bio-Techne Reports Q1 2026 Revenue and EPS Growth